枸橼酸莫沙必利分散片联合多酶片干预治疗沙利度胺致便秘的临床研究  

Observation on the efficacy of mosapride citrate dispersible tablet combined with mutienzyme tablets in the management of constipation due to thalidomide

作　　者：张呈[1] 苏铭俊[1] 容庭杰 钟建雄[1] ZHANG Cheng;SU Mingjun;RONG Tingjie;ZHONG Jianxiong(Xinhui People＇s Hospital,Jiangmen 529100,China)

机构地区：[1]江门市新会区人民医院,广东江门529100

出　　处：《临床医药实践》2018年第9期649-651,共3页Proceeding of Clinical Medicine

摘　　要：目的:观察枸橼酸莫沙必利分散片联合多酶片干预治疗沙利度胺致便秘的临床疗效。方法:将138例经沙利度胺治疗所致便秘的血液病患者随机分为三组,A组为观察组,口服枸橼酸莫沙必利分散片,每次5 mg,每日3次,多酶片每次2片,每日3次。B、C两组为对照组,B组口服枸橼酸莫沙必利分散片,每次5 mg,每日3次;C组口服乳果糖,每次10 m L,每日3次。三组患者均连续用药,2周后进行疗效比较分析,监测并及时记录出现的药物不良反应,随访观察治疗12个月内的复发率。结果:治疗2周后,三组的显效率分别为69.56%、21.74%和23.91%,临床总有效率分别为84.78%、47.82%和50.00%,A组的显效率和总有效率均显著高于B组、C组,差异有统计学意义(P<0.05);A组复发率明显降低,与B、C组比较,差异有统计学意义(P<0.05)。结论:枸橼酸莫沙必利分散片联合多酶片对沙利度胺致便秘疗效满意,安全性高。Objective： To investigate the efficacy of mosapride citrate dispersible tablet combined with mutienzyme tablets in the management of constipation due to Thalidomide.Methods： A randomized controlled study was carried out on 138 constipation patients due to thalidomide.The patients were random Ly divided into three groups： group A（ Combination therapy group）take mosapride citrate dispersible tablet 5 mg and mutienzyme tablets 2 pieces every time,3 times per day.Group B（ control group） take mosapride citrate dispersible tablet 5 mg every time,3 times per day.Group C（ control group） take lactulose oral solution 10 m L every time,3 times per day.After 2 weeks,the effect and adverse reactions,ease of symptoms and recurrence of three groups were compared and analyzed.Results： After 2 weeks treatment,the total effective rate of group A was 84.78%,statistically significantly higher than control groups（ P〈0.05）.Compared with control groups,the recurrence reduced significantly in group A（ P〈0.05）.Adverse reactions were not found significant in all three groups.Conclusion： The combination of mosapride citrate dispersible tablet and mutienzyme tablets in the treatment of constipation due to thalidomide has significantly clinical efficacy and high safety.

关 键 词：枸橼酸莫沙必利 多酶片 沙利度胺 便秘 

分 类 号：R574.62[医药卫生—消化系统]